SSSerhii M. Sudakevych

Serhii M. Sudakevych

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Serhii M. Sudakevych has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    USE OF LIDOCAINE IN A MULTIMODAL ANESTHESIA PROTOCOL FOR CORONARY ARTERY BYPASS GRAFTING WITH CARDIOPULMONARY BYPASS

    by Andrii Kandybor, Davyd Shabanov, Sofiia Chaikovska, Normunds Sikora, Serhii Sudakevych, Viktor Shevchenko, Gavrylo Kovtun, Borys Todurov

    Background. According to the American Heart Association, coronary artery disease is found in a significant share of people over 60 years old, and in Ukraine it remains one of the leading causes of mortality—approximately 650 cases per 100,000 population. Most coronary artery bypass grafting (CABG) procedures are performed using cardiopulmonary bypass (CPB), which may increase the risk of complications. In this regard, we aimed to evaluate the effectiveness of lidocaine as part of a multimodal analgesia regimen during such procedures. Objective. To analyze the impact of lidocaine administration on the level of surgical stress in patients undergoing CABG with CPB by assessing fluctuations in lactate, glucose, and the pro-inflammatory cytokine IL-6. Materials and Methods. The study is based on the results of examination of 100 patients with coronary artery disease (50 patients in Group 1 — without the use of lidocaine in the multimodal anesthesia scheme; 50 patients in Group 2 — with lidocaine). All underwent CABG with cardiopulmonary bypass. Indicators were recorded at the following stages: 1)before initiation of CPB; 2) after cessation of CPB; 3) on the last day in the intensive care unit. Results and Discussion. Before the start of surgery, hemodynamic indicators suggested stable overall condition. The duration of surgery in Group 2 (with lidocaine) was shorter by 9.95% compared to Group 1 (p=0.01); anesthesia duration decreased by 8.94% (p=0.02), and CPB duration decreased by 20.06% (p=0.0003). The fentanyl dose (µg/kg/min) in Group 2 was lower by 7.3% (p=0.03), and the amount of propofol (mg) was lower by 27.8% (p=0.0002). The total dose of dobutamine in Group 2 was lower by 25.08% (p=0.02). A significant difference was also observed in the level of the pro-inflammatory cytokine IL-6. By the end of CPB, its level in Group 2 was lower by 74.4% compared to Group 1 (p=0.008). The difference in lactate level was also statistically significant — by the end of perfusion it was lower by 11.16% (p=0.04) than in the group without lidocaine. On the last day in the intensive care unit, glucose levels in Group 2 were lower by 9% compared to Group 1 (p=0.02). Duration of mechanical ventilation decreased by 27.8% (p=0.0003), and norepinephrine dosage was lower by 44.1% (p=0.03). Conclusions. In the lidocaine group, a lower requirement for Fentanyl and Propofol was observed, as well as lower values of certain early postoperative parameters, including glucose levels, duration of mechanical ventilation, and the dose of Norepinephrine. Differences in the duration of surgery, anesthesia, cardiopulmonary bypass, and intraoperative requirement for Dobutamine should be interpreted as associations rather than definitive evidence of a direct causal effect of lidocaine. To conclusively confirm the obtained results, larger prospective studies with clearly defined randomization, comprehensive inclusion and exclusion criteria, as well as correlation analysis and multivariable statistical adjustment are warranted.

  • Open Access

    V-A ECMO-assisted primary percutaneous coronary intervention for STEMI without access to Impella: a single-center cohort study

    by B. M. Todurov, M. B. Todurov, S. R. Maruniak, S. M. Sudakevych, O. V. Zelenchuk, S. M. Chaikovska

    Primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI) may be complicated by imminent hemodynamic collapse. In the absence of access to microaxial pumps (e. g., Impella), veno-arterial extracorporeal membrane oxygenation (V-A ECMO) may represent the only full-support “protected PCI” option. The aim of the study was to evaluate the effectiveness and safety of planned V-A ECMO support during pPCI in high-risk STEMI patients in a setting without access to microaxial pumps. Materials and methods. We performed a prospective single-center cohort study at the State Institution “Heart Institute of the Ministry of Health of Ukraine” (Kyiv) which included selected adult patients with STEMI who underwent planned femoro-femoral V-A ECMO before the initiation of pPCI (surgical access). The study assessed angiographic success (final TIMI 3 flow), survival to discharge, neurological status at discharge assessed using the Cerebral Performance Category (CPC) scale, and in-hospital complications (BARC type 3 bleeding, limb ischemia/vascular surgery, acute kidney injury (AKI) and renal replacement therapy (RRT). Results. The study included 21 patients (median age 69 years [64; 75], 61.9 % male). Coronary disease complexity was high (SYNTAX score 29 [26; 32]); the culprit vessel was most commonly the left main coronary artery or left anterior descending artery (each 33 %). Median door-to-balloon time was 128 [109; 151] min. Final TIMI 3 flow was achieved in 85.7 % (18/21). Survival to discharge was 61.9 % (13/21) and in-hospital mortality was 38.1 % (8/21). Among the 13 surviving patients, 11 (84.6 %) had favorable neurological outcomes at discharge (CPC 1–2). Major bleeding (BARC 3) occurred in 23.8 % (5/21), limb ischemia in 9.5 % (2/21), and the need for vascular surgery in 9.5 % (2/21). AKI developed in 42.9 % (9/21) and RRT was required in 14.0 % (3/21). Median V-A ECMO duration was 72 [48; 96] h. Conclusions. In the absence of Impella, planned V-A ECMO-assisted pPCI in selected high-risk STEMI patients was associated with a high rate of coronary blood flow restoration, favorable neurological outcomes among survivors, and a complication profile typical for full mechanical circulatory support.

  • Open Access

    Impact of Histidine-Tryptophan-Ketoglutarate Solution Dosage on Early Myocardial Protection Outcomes in Patients with Reduced Left Ventricular Ejection Fraction Undergoing Isolated Valve Surgery: A Retrospective Cohort Study

    by Davyd V. Shabanov, Stepan R. Maruniak, Serhii M. Sudakevych, Borys M. Todurov

    Introduction. Optimization of myocardial protection is a key determinant of successful cardiac surgery, particularly in patients with reduced left ventricular ejection fraction (LVEF ≤40 %), who are at increased risk of developing low cardiac output syndrome (LCOS). Despite the widespread use of histidine-tryptophan-ketoglutarate (HTK) solution, the issue of optimal dosing remains insufficiently studied.Aim. To evaluate the impact of HTK solution dose on early postoperative outcomes in patients with reduced LVEF undergoing isolated mitral valve replacement.Materials and methods. A retrospective single-center cohort study was conducted in 84 patients (mean age 59.5±8.9 years; LVEF 31.7±5.0 %). All patients underwent surgery with cardiopulmonary bypass using HTK solution. Patients were stratified according to the indexed HTK solution dose (25 mL/kg). The primary endpoint was the development of LCOS; secondary endpoints included hemodynamic parameters, biomarkers of myocardial injury, and clinical outcomes.Results. The incidence of LCOS was 21.4 % and increased significantly with higher doses (13.6 % → 34.8 %; p=0.041). Higher doses were associated with an increased vasoactive-inotropic score at weaning from cardiopulmonary bypass (9.2±3.1 → 13.1±4.2; p<0.001) and at 24 hours (8.4±3.0 → 11.8±3.9; p=0.002), as well as a greater need for inotropic support beyond 48 hours (22.7 % → 39.1 %; p=0.048). Elevated levels of troponin I and CK-MB were observed with higher doses (p<0.01). In multivariable analysis, the HTK solution dose was an independent predictor of LCOS (OR 1.12; p=0.009), along with lower LVEF and longer aortic cross-clamp time.Conclusions. Higher doses of HTK solution are associated with worse early myocardial protection outcomes in patients with reduced LVEF. These findings highlight the need for individualized cardioplegia dosing, particularly in high-risk patients.

  • Open Access

    Predictors of Successful Weaning from Venous-Arterial Extracorporeal Membrane Oxygenation in Patients with Cardiogenic Shock Following Acute Myocardial Infarction

    by B. M. Todurov, M. B. Todurov, S. R. Maruniak, S. M. Sudakevych, O. V. Zelenchuk, S. M. Chaikovska

    Objective. To identify clinical, laboratory, and procedural predictors of successful weaning from veno-arterial extracorporeal membrane oxygenation in patients with cardiogenic shock following acute myocardial infarction who underwent percutaneous coronary interventions.Materials and Methods. A single-center retrospective cohort study included 57 consecutive adult patients with acute myocardial infarction complicated by cardiogenic shock who underwent percutaneous coronary interventions under veno-arterial extracorporeal membrane oxygenation between 2020 – 2025. The primary endpoint of the study was successful weaning from extracorporeal membrane oxygenation. Univariate and multivariate logistic regression analyses were used to identify independent predictors. The discriminatory ability of the predictors was assessed using ROC analysis.Results. Successful weaning from extracorporeal membrane oxygenation was achieved in 37 (64.9%) patients. The overall in-hospital mortality rate was 43.8%. Patients who were successfully weaned from extracorporeal membrane oxygenation had significantly lower lactate levels and a lower vasoactive-inotropic index than before the procedure began—5.1 (3.2–7.8) and 7.4 (4.6–10,9) mmol/L (p = 0.041) and 39 (28–52) and 52 (38–68) (p = 0.028), respectively. Intra-aortic balloon counterpulsation was used more frequently in patients with successful weaning than in those with unsuccessful weaning—51.4% and 15.0%, respectively (p = 0.008). A multivariate logistic analysis revealed that lactate levels (odds ratio 0.81 for each 1 mmol/L increase; 95% confidence interval 0.66–0.99; p = 0.041) and the use of intra-aortic balloon counterpulsation (odds ratio 4.12; 95% confidence interval 1.09–15.6; p = 0.034) were independent predictors of successful weaning from extracorporeal membrane oxygenation, whereas the vasoactive-inotropic index, after adjustment, did not retain statistical significance as an independent predictor. Lactate levels demonstrated good prognostic ability (area under the ROC curve 0.76) with an optimal cutoff value of 6.5 mmol/L.Conclusions. Among patients with acute myocardial infarction complicated by cardiogenic shock who underwent percutaneous coronary interventions using veno-arterial extracorporeal membrane oxygenation, the rate of successful weaning reached 64.9%, however, the overall in-hospital mortality remained high at 43.8%. Lower lactate levels and the use of intra-arterial balloon counterpulsation were independently associated with successful weaning from extracorporeal membrane oxygenation.

  • Open Access

    IMPACT OF THE TIMING OF RENAL REPLACEMENT THERAPY INITIATION ON TREATMENT OUTCOMES IN PATIENTS WITH CARDIAC SURGERY-ASSOCIATED ACUTE KIDNEY INJURY: A RETROSPECTIVE STUDY

    by Svitlana O. Romanenko, Iryna M. Shifris, Stepan R. Marunyak, Mykhailo B. Todurov, Sofia M. Chaikovska, Igor M. Kuzmych, Serhii M. Sudakevych

    Introduction. Acute kidney injury (AKI) following cardiac surgery remains one of the leading predictors of adverse clinical outcomes. Despite modern perfusion and intensive care technologies, the optimal timing of renal replacement therapy (RRT) initiation in AKI remains controversial.Aim. To assess the impact of RRT initiation timing on in-hospital mortality and renal function recovery in patients with AKI after cardiac surgery with cardiopulmonary bypass.Materials and methods. A retrospective single-center analysis was conducted in patients who underwent cardiac surgery with cardiopulmonary bypass between 2022 and 2025. Among 5,289 operated patients, AKI according to KDIGO criteria developed in 1,358 (25.7%), and 58 (4.27%) required RRT. Depending on treatment timing, patients were divided into early RRT initiation (n = 27; immediately after stage III AKI diagnosis) and delayed RRT initiation (n = 31; started for life-threatening indications and/or oliguria lasting more than 72 h). The primary endpoints were in-hospital mortality and renal recovery, including restoration of diuresis. Survival analysis and time to diuresis recovery were assessed using the Kaplan–Meier method and Cox regression.Results. At the time of RRT initiation, patients in the delayed group had a significantly worse metabolic profile and more severe renal impairment (higher creatinine, urea and serum potassium levels, and more pronounced acidosis; all p < 0.05). Early RRT was associated with shorter mechanical ventilation duration (58 [ 39–93] vs 66 [ 31–118] h; p = 0.038) and shorter ICU stay (12 [ 9–19] vs 15 [ 10–23] days; p = 0.045). Time to diuresis recovery was significantly shorter in the early RRT group (log-rank p = 0.015), and Cox regression showed a significantly higher probability of its recovery (HR = 2.37; 95% CI 1.15–4.91; p = 0.020). No statistically significant difference in in-hospital mortality was found between groups (29.6% vs 41.9%; p = 0.353).Conclusions. Early initiation of renal replacement therapy in patients with cardiac surgery-associated acute kidney injury is associated with faster renal recovery and reduced treatment intensity, but not with a significant reduction in mortality. These findings suggest that under current conditions early RRT mainly has an organ-protective rather than a life-saving effect.

  • Open Access

    One-Year Outcomes of Prophylactic Veno-Arterial Extracorporeal Membrane Oxygenation in High-Risk Percutaneous Coronary Intervention: A Single-Center Cohort Study

    by Borys M. Todurov, Mykhailo B. Todurov, Stepan R. Maruniak, Serhii M. Sudakevych, Sofia M. Chaikovska

    Background. High-risk percutaneous coronary intervention (HR-PCI) is increasingly performed in patients with complex coronary anatomy and severe left ventricular (LV) dysfunction. Mechanical circulatory support (MCS), including veno-arterial extracorporeal membrane oxygenation (V-A ECMO), is used to enhance procedural safety; however, its impact on long-term outcomes remains uncertain. Aim. To evaluate one-year clinical outcomes, safety, and prognostic determinants of prophylactic V-A ECMO use in patients undergoing HR-PCI. Materials and Methods. This prospective single-center observational study included 43 consecutive patients undergoing HR-PCI with planned V-A ECMO support between 2019 and 2025. The primary endpoint was all-cause mortality at 12 months. Secondary endpoints included major adverse cardiovascular and cerebrovascular events (MACCE), defined as a composite of death, myocardial infarction, stroke, and repeat revascularization. Left ventricular ejection fraction (LVEF) dynamics were also assessed. Results. Procedural success was achieved in 90.7 % of patients, with successful ECMO weaning in 88.4%. Major bleeding events classified as BARC 3-5 were observed in 20.9 % of patients, while vascular complications occurred in 11.6 %. Despite favorable periprocedural outcomes, all-cause mortality at 12 months was 25.6 %, and the incidence of MACCE was 46.5 %. Nonfatal myocardial infarction and stroke occurred in 4.7 % of patients each, while repeat revascularization was performed in 11.6 % of patients. Patients with baseline LVEF <30 % had significantly higher mortality (38.9 % vs. 16.0 %; p=0.048) and a higher incidence of MACCE (61.1 % vs. 36.0 %; p=0.048). Survival analysis demonstrated significantly lower one-year survival in this group (61 % vs. 84 %; log-rank p=0.048). A modest but statistically significant improvement in LVEF was observed at 6 and 12 months. Conclusions. Prophylactic V-A ECMO in HR-PCI provides high procedural success and effective hemodynamic stabilization; however, long-term outcomes remain primarily determined by baseline myocardial function. Severe left ventricular systolic dysfunction was a key predictor of adverse one-year outcomes, suggesting that V-A ECMO may improve procedural safety but does not necessarily translate into a significant long-term prognostic benefit.

  • Open Access

    Incidence and Risk Factors for Acute Kidney Injury Following Cardiac Surgery with Cardiopulmonary Bypass

    by S. O. Romanenko, S. R. Marunyak, B. M. Todurov, S. M. Chaykovska, H. I. Kovtun, O. V. Zelenchuk, N. O. Yashchenko, S. M. Sudakevych

    Objective: To determine the incidence and predictors of acute kidney injury following cardiac surgery with cardiopulmonary bypass. Materials and Methods. This study was based on a retrospective analysis of clinical data from 6,908 patients who underwent cardiac surgery with cardiopulmonary bypass at the Heart Institute of the Ministry of Health of Ukraine between 2022 and 2025. A total of 5,289 adult patients were included in the further analysis, of whom 1,358 (25.7%) developed acute postoperative kidney injury, defined according to the KDIGO classification (2024). The primary criterion for assessing acute kidney injury was the change in creatinine levels during the first 48 hours following surgery. Results. Multivariate logistic regression analysis identified the following factors as statistically significantly associated with an increased risk of postoperative acute kidney injury: elevated surgical risk according to the EuroSCORE II scale (odds ratio = 1.108; p < 0.001), urgent nature of the surgery (odds ratio = 1.827; p < 0.001), presence of diabetes mellitus (odds ratio = 1.442; p < 0.001), low hemoglobin level (odds ratio = 0.982; p = 0.002), prolonged cardiopulmonary bypass (odds ratio = 1.108; p < 0.001), the need for red blood cell transfusion (odds ratio = 1.389; p < 0.001), oxygen delivery below the minimum during cardiopulmonary bypass (odds ratio = 0.895, p = 0.039), and the use of deep hypothermic cardiopulmonary bypass (odds ratio = 1.823; p = 0.016). Conclusions. The incidence of acute kidney injury following cardiac surgery with cardiopulmonary bypass was 25.7%, which is consistent with data from international studies. Patients with postoperative acute kidney injury, compared to those without this complication, were older, had a higher surgical risk according to the EuroSCORE II scale, underwent urgent procedures more frequently, a higher prevalence of diabetes mellitus, lower preoperative hemoglobin and albumin levels, longer duration of cardiopulmonary bypass and aortic clamping, a greater need for red blood cell transfusion, as well as a reduction in the minimum oxygen delivery level during perfusion.

  • Open Access

    Метод ниркової замісної терапії та перебіг раннього післяопераційного періоду у пацієнтів з гострим пошкодженням нирок після кардіохірургічних втручань зі штучним кровообігом

    by Svitlana Romanenko, Stepan Marunyak, Sofia Chaikovska, Gavrylo Kovtun, Mykhailo Todurov, Serhii Sudakevych, Borys Todurov, Iryna Shifris

    Гостре пошкодження нирок (ГПН) після кардіохірургічних втручань зі штучним кровообігом асоціюється з підвищеною летальністю та тривалішим лікуванням у відділенні інтенсивної терапії (ВІТ). Оптимальний вибір модальності та режиму ниркової замісної терапії (НЗТ) залишається дискутабельним. Метою дослідження було оцінити частоту ГПН у пацієнтів після кардіохірургічних втручань зі штучним кровообігом та вплив різних методів та режимів НЗТ на перебіг раннього післяопераційного періоду у цієї категорії пацієнтів. Методи. До ретроспективного дослідження було включено 5289 пацієнтів, які перенесли кардіохірургічні втручання із застосуванням штучного кровообігу протягом 2022–2025 роках. ГПН визначали за критеріями KDIGO. Усі дорослі пацієнти, які потребували лікування діалізними методами, були розподілені на групи залежно від модальності та режиму НЗТ: інтермітуючий гемодіаліз (IHD, n=20), повільний низькоефективний діаліз (SLED, n=21) та безперервна ниркова замісна терапія (CRRT, n=17). Первинною кінцевою точкою дослідження була госпітальна летальність. Результати. Із загальної кількості пацієнтів, які перенесли кардіохірургічні втручання, ГПН розвинулося у 1358 випадках (25,7%), в тому числі, у 58 (4,27%) - потребувало лікування методами НЗТ. Групи пацієнтів були репрезентативні за демографічними, лабораторними та інтраопераційними характеристиками. У групі CRRT, порівняно з IHD та SLED, констатовано достовірно швидша нормалізація креатиніну та лактату (p<0,05 на 1–14-ту добу), стабільніший середній артеріальний тиск (p=0,032 – 0,041), нижча потреба у VIS (12,9±5,8 vs 21,3±7,5 у IHD та 18,1±6,8 у SLED; p=0,013) та тривалість ШВЛ (CRRT - 34 [24–60] год vs 68 [42–110] у IHD і 52 [36–88] у SLED; p=0,018). Окрім того пацієнти групи CRRT мали більш короткі терміни перебування у ВІТ (10 [4–15] доби; p=0,048) та загальної госпіталізації (19 [11–29] діб; p=0,028). У групі CRRT госпітальна летальність становила 23,5% проти 45,0% у групі IHD та 38,1% - у SLED (p=0,372), однак у багатофакторному аналізі лікування CRRT достовірно асоціювалося зі зниженням ризику смерті (OR 0,50; 95% ДІ 0,23–0,99; p=0,048). Незалежними предикторами летальності були лактат, MODS, тривалість ШВЛ, сепсис і максимальний VIS. Висновки. Частота ГПН у хворих після кардіохірургічних втручань зі штучним кровообігом склала 25,7%, в коженого четвертого - п'ятого (4,27%) пацієнта з ГПН виникла необхідність проведення НЗТ. Лікування CRRT, порівняно з іншими методами, асоціювалося як і з кращими результатами щодо перебігу раннього післяопераційного періоду, так і щодо зниження ризику летальності після корекції на тяжкість стану, особливо у гемодинамічно нестабільних пацієнтів.

  • Open Access

    Прогностичне значення ранньої динаміки лактату в пацієнтів з гострим інфарктом міокарда, ускладненим кардіогенним шоком, під час черезшкірних коронарних втручань із застосуванням вено-артеріальної екстракорпоральної мембранної оксигенації

    by B. M. Todurov, M. B. Todurov, S. M. Sudakevych, O. V. Zelenchuk, S. M. Chaikovska, S. R. Maruniak

    Acute myocardial infarction (AMI) complicated by cardiogenic shock is associated with high in-hospital mortality despite early revascularization and the use of mechanical circulatory support. Lactate is a marker of tissue hypoperfusion; however, its absolute value may not adequately reflect the effectiveness of therapy.The aim of this study was to evaluate the prognostic significance of early lactate dynamics in patients with AMI complicated by cardiogenic shock undergoing percutaneous coronary intervention (PCI) with veno-arterial extracorporeal membrane oxygenation (VA-ECMO).Materials and methods. A single-center retrospective cohort study included 57 patients with AMI and cardiogenic shock who underwent PCI with VA-ECMO support between 2021 and 2025. Lactate levels were measured before ECMO initiation (T0), and at 6 (T6) and 24 (T24) hours. Lactate clearance was calculated as a percentage. The primary endpoint was in-hospital mortality. Multivariable logistic regression analysis was performed to determine independent prognostic predictors.Results. In-hospital mortality was 36.8 %. Baseline lactate level (T0) did not differ between survivors and non-survivors (p=0.381). At 24 hours, lactate levels were significantly lower in survivors (p=0.032). Lactate clearance at 6 and 24 hours was significantly higher in survivors (p=0.013 and p=0.001, respectively). In multivariable analysis, 24-hour lactate clearance remained an independent predictor of in-hospital mortality (OR 0.71 per each 10 % increase; 95 % CI 0.55–0.93; p=0.013). According to ROC analysis, 24-hour lactate clearance demonstrated a moderate predictive ability for in-hospital mortality (AUC = 0.60). The optimal cutoff value for lactate clearance was approximately 72 %, with a sensitivity of 85.7 % and a specificity of 38.9 % for predicting mortality.Conclusions. In patients with AMI complicated by cardiogenic shock undergoing PCI with VA-ECMO support, early lactate dynamics – particularly 24-hour lactate clearance – has independent prognostic value for in-hospital mortality. Serial lactate monitoring may serve as an effective tool for early risk stratification and optimization of therapeutic strategy.

  • Open Access

    The Use of Marginal Donor Hearts as an Effective Way to Expand the Donor Pool in Heart Transplantation

    by S. Chaikovska, B. Todurov, G. Kovtun, M. Taranov, I. Kuzmych, S. Romanenko, V. Shevchenko, M. Todurov, S. Maruniak, S. Sudakevych

    Introduction. The critical shortage of donor organs is the main problem in the world to provide for a need treatment of patients with terminal heart disease. One of the ways to expand the donor pool may be to expand the criteria for selecting donor hearts using the so-called "marginal donors". The aim of our study was to analyze the early and long-term results of using hearts from marginal donors in orthotopic heart transplantation in patients with terminal stage chronic heart failure. Materials and methods. From December 2019 to October 2024, the heart transplantation team of the State Institution "Heart Institute of the Ministry of Health of Ukraine" performed 106 heart transplantations. In 39 (36.7%) cases, we used hearts from "marginal" donors for orthotopic heart transplantation, in 67 cases, orthotopic heart transplantation from classical donors was performed. Results. The criteria for donor marginality were the need for regional normothermic perfusion, the ratio between the mass of the donor and the recipient <0.8, the presence of concomitant cardiosurgical pathology of the donor organ (the need for revascularization, correction of valvular defect), prolonged ischemia time of the donor organ more than 240 min., ABO incompatibility, the presence of congenital heart disease. Orthotopic heart transplantation from marginal donors provided results comparable in both the early and long-term to those of standard donor hearts. Conclusions. The use of marginal donor hearts does not significantly affect the long-term outcomes of heart transplantation, which allows for a significant expansion of the donor pool, especially for patients with high status on the waiting list.